COVID-19
When SARS-CoV-2 emerged, ISARIC partners leveraged more than a decade of experience in acute respiratory outbreak research to assemble a comprehensive response to the global pandemic.
Existing protocols, established data systems and a prepared global network enabled us to collaborate quickly with hundreds of research ‘sites’ around the globe and generate evidence that contributed to policymaking, clinical trial designs and drug development to reduce the impact of the pandemic.
Working with hundreds of partners around the world, we assembled the world’s largest international collection of accessible data on individuals hospitalized with COVID-19. This dataset continues to help researchers and public health organisations around the world.
Characterising Disease
Optional CRF Modules
Modules to be used in addition to the Core or RAPID COVID-19 CRFs
MIS-C in children and adolescents
Stand alone CRF for children and adolescents.
Long COVID protocol
Follow-up clinical data collection
Long COVID paediatric
Paediatric protocol and survey for the follow-up of COVID-19 patients
Developing methodologies
COVID-19 Rapid Evidence Reviews Group (CORRE)
High quality rapid evidence synthesis for use in COVID-19 research.
Improving Treatment
Recovery (TBD) Trial
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Removing barriers
In response to the COVID-19 outbreak in Brazil, the ISARIC Hub in Brazil led a community engagement campaign with residents of one of Rio de Janeiro’s favela communities to increase COVID-19 acceptance and uptake. The Regional hub lead for South America, Dr Fernando Bozza partnered with a local NGO, Redes da Maré to carry out this campaign. The campaign was carried out in Maré, a territory consisting of 16 favelas and over 140,000 people. The learnings from engaging this community have been consolidated and published on our community engagement pages.
COVID-19 Research Partner Sites
Publications
Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study
Adults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid). However, existing evidence is scarce, partly due to a lack of a standardised case definition, short follow up duration, and heterogenous study designs, resulting in wide variation of reported outcomes. The primary aim of this study was to characterise risk factors for PCC and longitudinal rates of recovery in a cohort of children and young people using a standardised protocol. Learn more
Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19
Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies. Learn more
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospectve multinational observational study
The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Learn more
The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): a case study of bubonic plague
Among the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics for Neglected Tropical Diseases (NTDs) and diseases affecting the most vulnerable populations. Here we explore the impact of the pandemic on a clinical trial for plague therapeutics and strategies that have been considered to ensure research efforts continue. Learn more
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: A prospective, multicentre cohort study
COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections ... Learn more
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19
The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Learn more
Evaluating clinical characteristics studies produced early in the Covid-19 pandemic:a systematic review
Clinical characterisation studies have been essential in helping inform research, diagnosis and clinical management efforts, particularly early in a pandemic. This systematic review summarises the early literature on clinical characteristics of patients admitted to hospital, and evaluates the quality of evidence produced during the initial stages of the pandemic. Learn more
News
Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds
Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on children hospitalised with COVID 19.
Women under 50 had worse long-term outcomes after hospitalisation with COVID-19
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.
Key inflammatory markers identified in COVID-19
ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.
Activities
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Research priorities for Long Covid: refined through an international multi-stakeholder forum
Learn more